<code id='C955311248'></code><style id='C955311248'></style>
      • <acronym id='C955311248'></acronym>
      <center id='C955311248'><center id='C955311248'><tfoot id='C955311248'></tfoot></center><abbr id='C955311248'><dir id='C955311248'><tfoot id='C955311248'></tfoot><noframes id='C955311248'>
      • <optgroup id='C955311248'><strike id='C955311248'><sup id='C955311248'></sup></strike><code id='C955311248'></code></optgroup>
        5. <b id='C955311248'><label id='C955311248'><select id='C955311248'><dt id='C955311248'><span id='C955311248'></span></dt></select></label></b><u id='C955311248'></u>
          <i id='C955311248'><strike id='C955311248'><tt id='C955311248'><pre id='C955311248'></pre></tt></strike></i>
           
   
   
   
 

  
           
   
           
    
           
     
          
       Home / hotspot / comprehensive      
           
     
           
      
          comprehensive 
           
      
           
      
           
       2025-09-27 20:52:58 
   
      
           
      
           
                        
          comprehensive  
          
                                   
                 
                                      author：comprehensive   
                                        
                                      
                                      Page View：2933
                                  
                                    
          
                                   
          close-up of psoriasis on a hand. -- biotech coverage from STAT
          A close-up of psoriasis on a hand.																									Adobe 
          San Francisco startup Alumis Inc. has raised $259 million in a bid to best big pharma’s work in plaque psoriasis.
          Alumis announced its Series C round Wednesday and plans to move its lead drug into Phase 3 trials. Venture firm Foresite Capital, which incubated Alumis, co-led the financing with Samsara BioCapital and venBio Partners.
          advertisement
          Alumis’ lead drug, ESK-001, is an oral medicine designed to help patients with the most common type of psoriasis by inhibiting a signaling protein called TYK2. Research has shown that the TYK2 protein plays a role in diseases where the immune system overreacts, which has made it a popular drug target in recent years.
          Get unlimited access to award-winning journalism and exclusive events.					
          Subscribe																						Log In															
                      
                              
          
                                 Previous article：

                                
                                          Juul documents reveal insider tactics on political lobbying
                                
                            
          Next article：  
                                      
                                          The cancer drug shortage isn’t new — and neither are the solutions
                                                                    
          

      
           
    


       
       
       
    
     
           
    
           
    
           
   
      
     
           
      
           
       
          Related articles